Concepedia

METABOLISM AND EXCRETION OF ERLOTINIB, A SMALL MOLECULE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE, IN HEALTHY MALE VOLUNTEERS

Jie Ling, Kim A. Johnson, Zhuang Miao, Ashok Rakhit, Michael Pantze, Marta Hamilton, Bert L. Lum, Chandra Prakash

Drug Metabolism and Disposition · 2005 · 219 citations · 14 references

DOI

References

14

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 997 citations

Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer.

Jennifer R. Grandis, D J Tweardy · PubMed · 1993 · 859 citations

, , +18

BindingDB Entry 50022536: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

PubMed · 2025 · 844 citations · Full text

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Denis Soulières, Neil Senzer, Everett E. Vokes et al. · Journal of Clinical Oncology · 2003 · 803 citations · Full text

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 535 citations · Full text